Breast cancer therapy and age difference in cardiovascular disease risks: A population-based cohort study in Taiwan  by Tan, Chen Hui et al.
lable at ScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 98e103Contents lists avaiTaiwanese Journal of Obstetrics & Gynecology
journal homepage: www.t jog-onl ine.comOriginal ArticleBreast cancer therapy and age difference in cardiovascular disease
risks: A population-based cohort study in Taiwan
Chen Hui Tan a, 1, Ting-Ting Chao b, 1, Jui-Chen Liu c, Chun-Hung Lin d, h,
Yung-Sung Huang c, h, Chung-Ming Chang d, h, Hon-Yi Lin f, h, Yu-Chieh Su g, h,
Yen-Lin Chen i, *, Ching-Chih Lee e, h, *
a Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
b Medical Research Center, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
c Division of Neurology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
d Department of Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
e Department of Otolaryngology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
f Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
g Division of Hematology-Oncology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan
h School of Medicine, Tzu Chi University, Hualian, Taiwan
i Department of Pathology, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwana r t i c l e i n f o
Article history:
Accepted 4 June 2014
Keywords:
breast cancer
cardiovascular disease
chemotherapy
radiotherapy* Corresponding authors. Department of Patholo
Number 362, Chung-Cheng Road, Xindian, New Taip
Clinical Epidemiology and Biostatistics, Cancer Cent
gology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Me
Minsheng Road, Dalin Town, Chiayi County, 62224, Ta
E-mail addresses: anthonypatho@gmail.com (Y.-L
com (C.-C. Lee).
1 C.H.T. and T.T.C. contributed equally to this article
http://dx.doi.org/10.1016/j.tjog.2015.12.005
1028-4559/Copyright © 2016, Taiwan Association of O
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Objective: Cardiovascular events induced in breast cancer patients receiving radiotherapy (RT), chemo-
therapy (CT), or a combination of both (CRT) can increase the risk of death. This nationwide population-
based study aims to estimate the risk of cardiovascular complications with a follow-up period of 5 years.
Materials and Methods: The study cohorts consisted of all patients hospitalized with a principal diagnosis
of breast cancer who underwent treatment in 2002. The Cox proportional hazard model and Kaplan
eMeier plot were analyzed to compare the cardiovascular event-free survival rate among breast cancer
patients treated with different modalities.
Results: Of the 5514 breast cancer patients identiﬁed, 289 patients had cardiovascular disease (CVD): 110
(5.7%) from the surgery-alone group, 24 (4.1%) from the RT group, 79 (4.6) from the CT group, and 76
(5.8%) from the CRT group. Breast cancer patients who undergo CT and CRT at an age less than 55 years
had a higher risk of CVD when compared with the surgery-alone group (for both groups, p < 0.001). By
contrast, breast cancer patients aged over 55 years had no increased risk of CVD among the different
treatment modalities.
Conclusion: : Breast cancer patients receiving CT and/or CRT have a higher risk of CVD, especially younger
patients (aged < 55 years). Therefore, regular examinations of cardiac functions and electrocardiogram
should be considered in cases of young breast cancer patients who are receiving CT and/or CRT.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Breast cancer is the leading contributor to cancer mortality
among womenworldwide. Since 1990, the incidence and mortality
rates of breast cancer have increased annually. At present, the
incidence rate of breast cancer in Taiwan is approximately 59/
100,000 [1]. Treatment for breast cancer includes surgical inter-
vention and/or radiotherapy (RT), systemic treatment with cyto-
toxic chemotherapy (CT), hormone therapy, biologic therapy, or a
combination of these (CRT) [2].by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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a critical component of breast-conserving therapy for breast cancer,
has been discussed a lot with ischemic heart disease in numerous
studies [3e7,25]. However, caution must be exercised when
extrapolating the results of this meta-analysis, which included
older trials using outdated radiation techniques, to estimate risks
for patients treated in the modern era.
Based on data in the Surveillance, Epidemiology, and End-
Results (SEER) registries, the hazard ratio of cardiovascular dis-
ease (CVD) after receiving RT for women with left-side treatment
was 1.5 in 1979, but there were no signiﬁcant differences in rates of
hospitalization for ischemic heart disease, valvular heart disease,
conduction abnormalities, or heart failure between 1986 and 1993
[8].
At present, about one third of newly diagnosed cancers are
amenable to breast conservation; adjuvant systemic treatment is
recommended if a relevant reduction of the estimated risk of
recurrence and death can be expected with an acceptable level of
treatment-related adverse effects [9]. The use of anthracyclines,
which are chemotherapeutic agents with cardiotoxicity, may be
recommended for most breast cancer patients and especially for
those with human epidermal growth factor receptor type 2 (Her-
2)-positive disease [10]. A signiﬁcant increase in carotid intimal
thickness, myocardial perfusion, and laboratory risk factors of
atherosclerosis in patients treated with anthracycline-based CTwas
reported previously [11]. However, the actuarial incidence of car-
diovascular complications has not yet been clearly described in
Taiwan. In addition, age plays a key role in the development of CVD,
but it is scarcely discussed together with breast cancer patients in
the related literature. In this study, we sought to determine the
incidence of cardiovascular complications in breast cancer while
considering different therapies and age stratiﬁcation by utilizing
the National Health Insurance Research Database (NHIRD) in
Taiwan.
Materials and methods
Database
This study used data from the 2002e2007 NHIRD, which are
published by Taiwan's National Health Research Institutes. The
NHIRD covered themedical beneﬁt claims for approximately 97% of
the Taiwanese population, and contains a registry of board-certiﬁed
physicians and contractedmedical facilities. However, this database
does not contain information on tobacco use, dietary habits, and
body mass index. Because these data consist of deidentiﬁed sec-
ondary data released to the public for research, this study was
exempted from a full review by the Institutional Review Board.
The study cohort consisted of patients with breast cancer
[identiﬁed according to the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes
174.0e174.9] aged 20 years or older diagnosed in 2002 who had
undergone surgery, RT, CT, CRT, or surgery with adjuvant therapy.
Patients with any type of CVD, including ischemic heart disease
(ICD-9-CM 410e414) and congestive heart failure (ICD-9-CM 428),
diagnosed before or during the index admissionwere excluded. We
identiﬁed 5514 patients with breast cancer.
Measurements
The primary dependent variable in the study was CVD. We
utilized administrative data to identify all patients who developed
any type of CVDdischemic heart disease (ICD-9-CM 410e414) and
congestive heart failure (ICD-9-CM 428). Each breast cancer patient
was traced back from the initial hospitalization date since 2002 tothe end of 2007. CVD-free survival time was then calculated, with
cases censored if the patient died from noncardiovascular causes
during the follow-up period. We compared the outcomes for pa-
tients who underwent surgery alone, RT with or without surgery,
CT with or without surgery, and CRT with or without surgery. The
four groups were analyzed separately to account for the likelihood
that a patient who undergoes RT or CRT might receive a higher
radiation dose or other predisposing factors for a CVD, such as CT
regimen, than those undergoing surgery alone. The age of 55 was
used to divide the patients as young and old breast cancer patients
according to the American Heart Association's scientiﬁc statement
on cardiovascular risk factors. The independent variables were
comorbidities, geographic area of residence, urbanization level, and
socioeconomic status.
Statistical analysis
The SAS statistical package (version 9.2; SAS Institute, Inc., Cary,
NC, USA) and SPSS (version 15, SPSS Inc., Chicago, IL, USA) were
used to analyze the data. The cumulative risk of cardiovascular
event was estimated as a function of time from initial treatment.
Pearson Chi-square tests were used to explore the differences be-
tween categorical variables in the different treatment groups. Car-
diovascular event-free survival rate was estimated using the
KaplaneMeier method, and the Cox proportional hazard regression
model was used to calculate the relative risk of breast cancer pa-
tients between different treatment modalities after adjusting for
the aforementioned variables. A p value less than 0.05 was
considered statistically signiﬁcant.
Results
For the 5514 breast cancer patients identiﬁed in this study, the
median follow-up duration was 5.3 years (interquartile range
5e5.7 years). The mean age of the entire cohort was 51 years
(standard deviation 12 years). A total of 1914 (35%) patients un-
derwent surgery alone, 580 (10%) patients received RT, 1708 (31%)
patients received CT, and 1312 (24%) patients received CRT. Table 1
presents the demographic characteristics of breast cancer patients
according to different treatment modalities. Patients who under-
went surgery alone were more likely to be older, to have lower
Charlson Comorbidity Index Scores, to reside in Northern Taiwan, to
be living in urban areas, and to have locoregional diseases.
At the end of the follow-up period, 289 patients were found to
have CVD: 110 (5.7%) from the surgery-alone group, 24 (4.1%) from
the RTgroup, 79 (4.6) from the CTgroup, and 76 (5.8%) from the CRT
group. An interaction effect between CVD incidence and age groups
was observed, and thus, the study cases were further stratiﬁed into
four groups by age: less than 45 years old, 45e54 years old,
55e64 years old, and more than 65 years old (Table 2). Breast
cancer patients who underwent CT and CRT at an age less than
55 years carried a higher risk of CVD when compared with the
surgery-alone group (both groups p < 0.001; Table 3). There was no
signiﬁcant difference between the four groups at age 55 years or
older. Figure 1 shows a signiﬁcant difference in the increase in CVD
risk for patients in the CT and CRT groups aged 55 or less with the p
value less than 0.001. By contrast, breast cancer patients older than
55 years had no increasing risks of CVD between different treat-
ment modalities.
Discussion
Our study shows that young breast cancer patients aged less
than 55 years who undergo CT or CRT are at an increased risk of
subsequent CVD. The hazard ratio of developing CVD among breast
Table 1
Demographic characteristics for breast cancer patients by different treatment modalities.
Variables Surgery alone (n ¼ 1914) RT (n ¼ 580) CT (n ¼ 1708) CRT (n ¼ 1312) p
Age (y)
<45 507 (26.5) 204 (35.2) 546 (32.0) 489 (37.3) 0.001
45e54 647 (33.8) 201 (34.7) 654 (38.3) 479 (36.5)
55e64 357 (18.7) 96 (9.6) 314 (18.4) 238 (18.1)
>65 403 (21.1) 79 (13.6) 194 (11.4) 106 (8.1)
CCIS
0e6 1499 (78.3) 344 (59.3) 929 (54.4) 324 (47.6) <0.001
>6 415 (21.7) 236 (40.7) 779 (45.6) 688 (52.4)
Enrollee category
1e2 1094 (57.2) 306 (52.8) 920 (53.9) 771 (58.8) 0.026
3 654 (34.2) 228 (39.3) 648 (37.9) 451 (34.4)
4 166 (8.7) 46 (7.9) 140 (8.2) 90 (6.9)
Geographic region
Northern 1125 (58.8) 303 (52.2) 892 (52.2) 629 (47.9)
Central 425 (22.2) 139 (24.0) 403 (23.6) 386 (29.4) <0.001
Southern 343 (17.9) 129 (22.2) 395 (23.1) 276 (21.0)
Eastern 21 (1.1) 9 (1.6) 18 (1.1) 21 (1.6)
Urbanization
Urban 805 (42.1) 205 (35.3) 582 (34.1) 449 (34.2) <0.001
Suburban 799 (41.7) 282 (48.6) 792 (46.4) 609 (46.4)
Rural 310 (16.2) 93 (16.0) 334 (19.6) 254 (19.4)
Tumor characteristics
Locoregional 1899 (99.2) 507 (87.4) 1488 (87.1) 1191 (90.8) <0.001
Distant metastasis 15 (0.8) 73 (12.6) 220 (12.9) 121 (9.2)
Data are presented as n (%).
CCIS ¼ Charlson Comorbidity Index Score; CRT ¼ chemoradiotherapy ± surgery; CT ¼ chemotherapy ± surgery; RT ¼ radiotherapy ± surgery.
Table 2
Crude and adjusted hazard ratio of cardiovascular disease among breast cancer patients by age stratum in different treatment modalities.
Diagnosed age RT vs. surgery alone CT vs. surgery alone CRT vs. surgery alone
Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p
<45 1.87
(0.78e4.52)
0.224 1.42
(0.72e2.64)
0.348 2.16
(0.82e5.70)
0.118 1.85
(0.68e5.04)
0.227 2.52
(0.96e6.64)
0.061 2.13
(0.78e5.81)
0.139
45e54 2.62
(0.91e7.55)
0.075 2.48
(0.85e7.17)
0.095 3.94
(1.80e8.61)
0.001 4.01
(1.82e8.83)
0.001 5.98
(2.75e13.0)
<0.001 6.15
(2.77e13.63)
<0.001
5564 0.94
(0.39e2.27)
0.882 0.75
(0.30e1.90)
0.545 0.93
(0.52e1.69)
0.816 0.84
(0.45e1.56)
0.571 0.75
(0.39e1.51)
0.413 0.72
(0.35e1.48)
0.368
>65 1.01
(0.55e1.86)
0.979 1.06
(0.57e1.98)
0.857 0.60
(0.36e1.01)
0.053 0.82
(0.48e1.41)
0.473 1.49
(0.91e2.43)
0.109 2.16
(1.27e3.69)
0.005
All patients 0.77
(0.50e1.20)
0.246 0.97
(0.62e1.51)
0.882 0.87
(0.65e1.17)
0.359 1.24
(0.92e2.53)
0.161 1.14
(0.85e1.53)
0.359 1.84
(1.34e2.53)
<0.001
Adjusted variables were the patients' age at diagnosis, sex, Charlson Comorbidity Index Score, socioeconomic status, urbanization of residence, and geographic region of
residence.
95% CI ¼ 95% conﬁdence interval; CRT ¼ chemoradiotherapy ± surgery; CT ¼ chemotherapy ± surgery; HR ¼ hazard ratio; RT ¼ radiotherapy ± surgery.
Table 3
Crude and adjusted hazard ratio of cardiovascular disease among the breast cancer patients by treatment modality between young and old age groups.
Treatment modality
Age < 55 y Age  55 y
CVD/Total
(%)
Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p CVD/Total
(%)
Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p
Surgery alone 14/1154 (1.2) Reference d Reference d 96/760 (12.6) Reference d Reference d
RT 6/405 (1.5) 1.30
(0.50e3.39)
0.590 1.30
(0.50e3.39)
0.594 18/175 (10.3) 0.90
(0.54e1.49)
0.677 0.98
(0.89e1.64)
0.944
CT 42/1200 (3.5) 3.14
(1.72e5.75)
<0.001 3.00
(1.63e5.54)
<0.001 37/508 (7.3) 0.63
(0.43e0.92)
0.018 0.88
(0.59e1.32)
0.541
CRT 44/968 (4.5) 4.24
(2.32e7.73)
<0.001 4.22
(2.27e7.83)
<0.001 32/344 (9.3) 0.86
(0.57e1.28)
0.449 1.33
(0.86e2.05)
0.198
Adjusted variables were the patient's age at diagnosis, sex, socioeconomic status, urbanization of residence, and geographic region of residence.
95% CI ¼ 95% conﬁdence interval; CRT ¼ chemoradiotherapy ± surgery; CT ¼ chemotherapy ± surgery; CVD ¼ cardiovascular disease; HR ¼ hazard ratio;
RT ¼ radiotherapy ± surgery.
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times higher in patients receiving surgery alone, and 4.22 times
higher in patients receiving CRT after adjusting for other factors.The incidence of CVD was much higher in patients older than
55 years of age regardless of treatment modalities. Similar results
were seen in the KaplaneMeier plot with the p value set at less than
Figure 1. Cardiovascular event-free risk over time by treatment groups in breast cancer in patients aged (A) less than 55 and (B) more than 55 years. CT ¼ chemotherapy ± surgery;
CVD ¼ cardiovascular disease; RT ¼ radiotherapy ± surgery; CRT ¼ chemoradiotherapy ± surgery; þ  surgery ¼ with or without surgery.
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interesting points of information to existing knowledge on the
incidence of CVD among breast cancer patients. Using a population-
based dataset, the incidence of CVD increasedmore in the CTand/or
CRT group rather than in the RT group alone in breast cancer pa-
tients younger than 55 years of age at the time diagnosis of the
disease.
Breast cancer is treated with a multidisciplinary approach
involving surgery, radiation oncology, and CT, which has been
associated with a reduction in breast cancer mortality [12]. Anti-
cancer therapies have led to a long life expectancy; however,
because cardiac toxicity is one of most serious potential side effects,
the gain in life expectancy due to anticancer therapy might be
countered by an increased mortality due to cardiac problems, heart
failure, myocardial ischemia, arrhythmias, hypertension, and
thromboembolism [13]. A wide range of CT agents has been asso-
ciated with cardiotoxicity. The anthracyclines (doxorubicin,
daunorubicin, idarubicin, and epirubicin) are the most frequently
implicated agents associated with cardiotoxicity, which are the
commonly used regimen in breast cancer treatment [14]. In ameta-
analysis of eight trials comparing an anthracycline-containing
versus a nonanthracycline-containing CT regimen, use of anthra-
cyclines was associated with a signiﬁcantly increased risk of both
clinical [odds ratio (OR) 5.43, 95% conﬁdence interval (CI)
2.34e12.62] and subclinical cardiotoxicity (OR 6.25, 95% CI
2.58e15.13) [15]. Cardiac toxicity of anthracyclines involves
oxidative stress and apoptosis [16]. Therefore, it is logical to hy-
pothesize that using anthracycline as the main CT or CRT regimen
might play a larger part in increasing CVD risk, compared with
using only a surgical approach.
In addition, the Her-2-positive breast cancer patients are
routinely treated with trastuzumab in Taiwan at present. Heart
failure, a serious side effect, occurs in 1e4% of patients treated with
trastuzumab, and 10% of patients have been observed to have a
decrease in cardiac function [17]. Moreover, the combination of
anthracyclines and trastuzumab in CRT appears to increase the
incidence of cardiac side effects, which mediates cardiac failure in a
direct, dose-dependent manner. Therefore, many clinical trials have
been carried out on this topic to evaluate the treatment effects of
trastuzumab. The Herceptin Adjuvant trial [18] focused on early
breast cancer and showed that cardiac end points were higher in
the trastuzumab group compared with observation (severecongestive heart failure, 0.60% vs. 0.00%; symptomatic congestive
heart failure, 2.15% vs. 0.12%; conﬁrmed signiﬁcant left ventricular
ejection fraction drops, 3.04% vs. 0.53%) [18]. Subsequently, a
similar-designed study with a long-term follow-up (median
3.6 years) showed that the incidence of cardiac end points
remained low, although it was higher in the trastuzumab group
than in the observation group [19]. Concerning the late-stage
metastatic breast cancer patients, the Herceptin, Cyclophospha-
mide, and Epirubicin trial evaluated the effect of trastuzumab plus
cyclophosphamide and the less cardiotoxic anthracycline epi-
rubicin on the dose-limiting cardiotoxicity. In that trial, the tras-
tuzumab arm had a higher level of manageable cardiac adverse
effects [20]. The underlying mechanisms may be revealed by the
Her-2-deﬁcient mouse model. The induction of cardiac stress
pathways by either hemodynamic overload or the cardiotoxicity of
anthracyclines promotes the onset of left ventricular dysfunction
due to the action of ErbB2eErbB4 heterodimeric receptors, which
are important in triggering the myocyte-survival pathways [21,22].
These studies [21,22] support a two-hit model of trastuzumab
cardiotoxicity, in which there is a loss of ErbB2-mediated pathways
that normally blunt the effects of stress-signaling pathways acti-
vated by anthracyclines in the heart.
In our series, there was no statistical difference between the
CVD incidence and treatment modalities in breast cancer patients
aged 55 years and above. One of the most possible mechanisms is
that increased competing mortality in older breast cancer patients
masks the risk of CT and CRT. Breast cancer patients may die of
index cancer and other conditions, such as sepsis, pneumonia, or
stroke. Compared with younger breast cancer patients, older pa-
tients tend to have more comorbidities, an independent predictor
of competing mortalities. Older patients may die of cancer or
competing mortality prior to CVD manifestation. Another reason
may be related to the myocardium injury, degeneration of endo-
thelium, and adventitial ﬁbrosis resulting from CT or CRT [8]. This
effect is especially signiﬁcant in young breast cancer patients aged
between 45 years and 54 years. A similar phenomenon high-
lighting those young patients who developed a more severe
atherosclerotic response than the reference group has already
been reported [23]. In animal studies, the wound repair process
becomes slower with advancing age and these age-related
changes in the wound-repairing process might partially explain
our results. However, further studies are necessary to explore the
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therapy for breast cancer.
RT, a critical component in breast-conserving therapy for breast
cancer patients, has been evolving dramatically over the past
several decades [24]. Although the association between breast
cancer and ischemic heart disease has been discussed in numerous
studies, several contrasting reports have also been published in
recent years [3e7]. In a previous meta-analysis, breast cancer pa-
tients receiving RT in clinical trials have had signiﬁcant excess
mortality from heart disease (rate ratio 1.27, p < 0001) [25]. How-
ever, caution must be exercised when extrapolating the results of
this meta-analysis, which included older trials using outdated ra-
diation techniques to estimate risks for patients treated in the
modern era [26]. A large population-based analysis, based on data
in the SEER registries, of women treated for breast cancer from
1973 to 1989 suggested that the increased risk of ischemic heart
disease associated with RT has decreased over time [27]. A single-
institution retrospective review of cardiovascular death rates in
patients treated with postmastectomy radiation between 1975 and
1994 documented very low rates of death from myocardial infarc-
tion [28]. Still, another SEER-based study found breast cancer sur-
vivors to have a diminished risk of acute myocardial infarction
requiring hospitalization [29]. However, it is difﬁcult to determine
whether the low rate of events in these series simply reﬂects a
lower baseline risk of ischemic cardiac disease in the breast cancer
patient population, or whether it truly indicates that RT adminis-
tered during that period had little effect on related risk. In fact,
cardiac perfusion defects have been reported in patients treated
from 1998 to 2002 [30], but the clinical consequences of these
changes in cardiac perfusion are not yet clear. Another issue with
treating breast cancer and CVD with RT involves the side treated by
RT (i.e., right- or left-sided treatment). In 1979, the hazard ratio for
women with left-sided treatment was 1.5, but the hazard of death
from ischemic heart disease decreased by 6% with each succeeding
year [31]. When investigators compared cardiac morbidity in breast
cancer patients from 1986 to 1993 in another SEER-based study,
they found no signiﬁcant differences in rates of hospitalization for
ischemic heart disease, valvular heart disease, conduction abnor-
malities, or heart failure [8]. By the 1980s, most radiation oncolo-
gists had abandoned cobalt units and outdated techniques such as
deep tangents and en face “hockey stick” ﬁelds and began to
routinely treat breast cancer patients with standard tangents using
megavoltage linear accelerators [26]. In more recent years, some
centers also began to use three-dimensional CT-based planning for
left-sided breast cancers, which is particularly useful for mini-
mizing cardiac irradiation [26,32].
The strength of our study is using the nationwide population-
based cohort databank for analysis. The large number of study pa-
tients may reduce some selection bias. However, there are still
several limitations in this study that should be highlighted. First, the
diagnosis of breast cancer, CVD, and any other comorbid conditions
is completely dependent on ICD codes. Nonetheless, the National
Health Insurance Bureau of Taiwan randomly reviews the charts and
interviews patients to verify the accuracy of diagnosis. The breast
cancer patients are further veriﬁed by the registry for the cata-
strophic illness patient database. Second, the regimen of CT, dose
and type of RT, and the severity and territory of the CVD cannot be
precisely extracted from the NHIRD, which prevented further sub-
group analysis. For example, trastuzumab, a recombinant human-
ized monoclonal antibody, which targets the Her-2 and inhibits
carcinoma cellular proliferation mentioned earlier [33], was re-
ported by Piotrowski et al [34] to have a higher incidence of cardiac
complications. Tamoxifen and other selective estrogen receptor
modulators reduce levels of plasma cholesterol and homocysteine
but increase the level of serum triglyceride [35e37] and wereassociated with higher rates of venous thromboembolic disease and
stroke [38]. Finally, further research linking primary hospitalization
or ambulatory settings information such as types of CVD, severity,
and detailed risk factors is worthy of future investigation.
In conclusion, breast cancer patients receiving CT and/or CRT
have a higher risk of CVD, especially younger patients
(aged < 55 years). Therefore, regular examinations of cardiac
functions and electrocardiogram should be considered in cases of
young breast cancer patients who are receiving CT and/or CRT.
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